<DOC>
	<DOCNO>NCT01983969</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose azacitidine give vorinostat , gemcitabine , busulfan , melphalan , stem cell transplant , without rituximab . Researchers also want learn safety level effectiveness combination .</brief_summary>
	<brief_title>Aza-SAHA-GBM With AutoSCT Refractory Lymphoma</brief_title>
	<detailed_description>Study Groups : If find eligible take part study agree , assign dose level azacitidine base join study . Up 7 dose level azacitidine test . At least 3 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose azacitidine find . All participant receive dose level vorinostat , gemcitabine , busulfan , melphalan , patient B-cell cancer receive dose rituximab . However , first group bad side effect , dose level gemcitabine may lower group . Busulfan Test Dose : You receive test dose busulfan vein 60 minute . This low-level test dose busulfan check level busulfan blood level change time . This information use decide next dose need reach target blood level match body size . You likely receive outpatient week admit hospital . If give outpatient , admitted hospital Day -12 ( 12 day stem cell return body ) test dose give Day -11 . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test busulfan . PK test measure amount study drug body different time point help study doctor determine dose busulfan study . These blood sample draw various timepoints receive busulfan next 11 hour . The blood sample repeat first day high-dose busulfan treatment ( Day -8 ) . A temporary heparin lock line place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . On Days -14 , -13 , -12 , receive palifermin vein 30 second day help decrease risk side effect mouth throat . Study Drug Administration ( patient ) : In stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . Beginning Day -9 , swish liquid caphosol glutamine mouth 4 time day , 2 minute time . You swish liquid every day leave hospital . You swallow glutamine . These drug use help decrease risk side effect mouth throat . On Day -11 Day -2 , take vorinostat mouth , food . One hour later day , receive azacitidine vein 1 hour . You receive dexamethasone vein 2 time day . If B-cell cancer , receive rituximab ( treatment use certain lymphoma ) vein 3-6 hour part standard care , Day -9 . On Day -8 , receive gemcitabine vein 4 ½ hour . On Days -8 , -7 , -6 , -5 , receive busulfan vein 2 hour . On Day -3 , receive gemcitabine vein 4 ½ hour melphalan vein 30 minute . On Day -2 , receive melphalan vein 30 minute . On Day -1 , rest ( receive chemotherapy ) . On Day 0 , receive stem cell vein 30-60 minute . You receive 3 dos palifermin vein 15-30 second Days 0 , +1 , +2 . As part standard care , receive G-CSF ( filgrastim ) injection skin 1 time day start Day +5 blood cell level return normal . Study Tests : About 100 day transplant : - You physical exam . - Blood ( 4 teaspoon ) urine collect routine test . - If doctor think need , may bone marrow aspiration biopsy check status disease . To collect bone marrow aspiration/biopsy , area hip numb anesthetic , small amount bone marrow bone withdrawn large needle . Length Study : As part standard care , remain hospital 3-4 week transplant . After release hospital , continue outpatient Houston area monitor infection transplant-related complication . You take study 100 day transplant . You may take study early disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Azacitidine , vorinostat , gemcitabine , busulfan , melphalan , rituximab FDA approve commercially available . The use study drug combination investigational . Up 60 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<criteria>1 . Age 15 65 year . 2 . Patients Hodgkin 's lymphoma one following : ) Less complete response firstline chemotherapy . b ) Relapse within 12 month completion firstline chemotherapy . c ) Relapse within prior irradiation field . ) Less complete metabolic response secondline chemotherapy . e ) Second relapse beyond . f ) Extranodal disease time relapse . g ) Presence B symptom time persistent disease upon completion firstline chemotherapy , relapse progressive disease . h ) Bulky disease ( define lesion great 5 cm ) time persistent disease upon completion firstline chemotherapy , relapse progressive disease . 3 . Patients nonHodgkin 's lymphoma one following : 1 . Diffuse large Bcell lymphoma one following : ) Primary refractory disease . b ) Relapse within 12 month completion firstline therapy . c ) Secondary IPI &gt; 1 . ) Less PR firstline salvage chemotherapy . e ) Kinetic failure salvage chemotherapy ; f ) Prior treatment 3 line therapy . g ) Patients doublehit triplehit NHL , state disease . 2 . Peripheral Tcell lymphoma otherwise specify ( PTCLNOS ) stage disease . 3 . Angioimmunoblastic Tcell lymphoma ( AITL ) stage disease . 4 . Refractory recurrent Burkitt¹s lymphoma . 5 . Any lymphoma refractory relapse qualify treatment protocols high priority . 4 . Adequate renal function , define estimate serum creatinine clearance &gt; /=50 ml/min ( MDRD method National Kidney Disease Education Program , NKDEP ) and/or serum creatinine &lt; /= 1.8 mg/dL . 5 . Adequate hepatic function , define SGOT and/or SGPT &lt; /= 3 x upper limit normal ; serum bilirubin alkaline phosphatase &lt; /= 2 x upper limit normal . 6 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /= 50 % expect corrected hemoglobin . 7 . Adequate cardiac function leave ventricular ejection fraction &gt; /= 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 8 . Zubrod performance status &lt; 2 . 9 . Negative Beta HCG text woman childbearing potential , define postmenopausal 12 month previous surgical sterilization . 1 . Patients grade &gt; /= 3 nonhematologic toxicity previous therapy resolve &lt; /= grade 1 . 2 . Patients prior whole brain irradiation . 3 . Patients active hepatitis B , either active carrier ( HBsAg + ) viremic ( HBV DNA &gt; /=10,000 copies/mL , &gt; /= 2,000 IU/mL ) . 4 . Evidence either cirrhosis stage 34 liver fibrosis patient chronic hepatitis C positive hepatitis C serology . 5 . Patients active inflammatory bowel disease . 6 . Active infection require parenteral antibiotic . 7 . HIV infection , unless patient receive effective antiretroviral therapy undetectable viral load normal CD4 count . 8 . Patients receive radiation therapy month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Advanced Cancers</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Recurrent Hodgkin 's</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-azacytidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
	<keyword>Caphosol</keyword>
	<keyword>Glutamine</keyword>
	<keyword>Enterex</keyword>
	<keyword>Glutapak-10</keyword>
	<keyword>NutreStore</keyword>
	<keyword>Resource</keyword>
	<keyword>GlutaSolve</keyword>
	<keyword>Sympt-X G.I .</keyword>
	<keyword>Sympt-X</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
</DOC>